Patent · US Active

Hepatitis C virus inhibitors

US8735398B2 · kind B2 · utility

6Cited by

3References

15Claims

0Family size

Assignee

Bristol-Myers Squibb Company · US

Inventors

Omar D. Lopez · Wallingford, US
Denis R. St. Laurent · Newington, US
Jason Goodrich · Meriden, US
Jeffrey Lee Romine · Meriden, US
Michael H. Serrano-Wu · Cambridge, US
Fukang Yang · Madison, US
Ramesh Kakarla · Doylestown, US
Xuejie Yang · Longbeilingcun, CN
Yuping Qiu · Princeton Junction, US
Lawrence B. Snyder · Killingworth, US

Key dates

Filing date	Nov 7, 2012
Grant date	May 27, 2014
Priority date	—
Expiry date	Nov 7, 2032

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D471/04
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present disclosure is generally directed to antiviral compounds, and more specifically directed to compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such compounds, and methods for inhibiting the function of the NS5A protein.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.